Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor
July 5, 2018
-
REGULATORY Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
-
TRENDS Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
-
REGULATORY MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
-
BUSINESS Takeda Celebrates Grand Opening for New Global Headquarters
July 3, 2018
-
BUSINESS With Focus on CGRP, Development of New Generation of Preventive Treatments for Migraines Heating Up
July 2, 2018
-
BUSINESS Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
June 29, 2018
-
BUSINESS Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
-
BUSINESS Keytruda’s MSI-H Cancer Indication to Be Reviewed Under Conditional Early Approval System
June 28, 2018
-
BUSINESS Chugai Chairman Prods Drug Makers to Innovate, Chides Calls for Relaxed Pricing
June 27, 2018
-
ACADEMIA Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
-
BUSINESS Xofluza Likely to Jolt Japan Flu Market This Winter
June 25, 2018
-
BUSINESS Maviret Sweeping Japan Hep C Market, 80% Share Snatched in Just 4 Months?
June 22, 2018
-
ACADEMIA Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
-
TRENDS Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
-
REGULATORY PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
June 19, 2018
-
ORGANIZATION Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
June 18, 2018
-
REGULATORY Authorized Generics for Aimix, Cravit IV Join NHI Price List
June 15, 2018
-
REGULATORY Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
June 14, 2018
-
REGULATORY Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…